SCHEMBL1436095

SCHEMBL1436095

COc1ccc(C(=O)N(C)O)cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.63
CYP2C9 P11712 2/20 0.63
CYP2C19 P33261 2/20 0.63
CYP1A2 P05177 2/20 0.63
CYP3A4 P08684 1/20 0.63
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA4 P22748 1/20 0.61
CA6 P23280 1/20 0.61
CA7 P43166 1/20 0.61
TPMT P51580 1/20 0.61
CA9 Q16790 1/20 0.61
CA14 Q9ULX7 1/20 0.61
ELANE P08246 1/20 0.58
MAPT P10636 4/20 0.57
LMNA P02545 1/20 0.57
ALDH1A1 P00352 2/20 0.56
HPGD P15428 1/20 0.56
BACE1 P56817 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30486023 1.00 TSHR (0.63) TSHRCYP2C9CYP2C19CYP1A2CYP3A4
SCHEMBL6409033 0.87 CYP2C9 (0.66) TSHRCYP2C9CYP2C19CYP1A2CYP3A4
SCHEMBL4183893 0.83 KMT2A (0.65) MAPTLMNAALDH1A1POLBSMN1; SMN2
SCHEMBL14388233 0.81 CYP2C9 (0.63) TSHRCYP2C9CYP2C19CYP1A2CYP3A4
SCHEMBL17035531 0.81 CYP2C9 (0.58) TSHRCYP2C9CYP2C19CYP1A2CYP3A4
SCHEMBL1436447 0.79 TUBB4A (0.50) TSHRCYP3A4TPMTMAPTLMNA
SCHEMBL10566813 0.79 CTSL (0.46) TSHRCYP2C9CYP2C19CYP1A2CYP3A4
SCHEMBL10566336 0.79 CTSL (0.46) TSHRCYP2C9CYP2C19CYP1A2CYP3A4
SCHEMBL13216464 0.79 HSP90AA1 (0.77) TSHRCYP2C9CYP2C19CYP1A2CYP3A4
SCHEMBL17321082 0.78 L3MBTL1 (0.64) TSHRCYP2C9CYP2C19CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181306-A1 BIOLOGICALLY MODIFIED VASCULAR GRAFTS FOR IMPROVED BYPASS SURGERY OUTCOMES THE BOARD AND TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2023-06-15 US claimed
EP-3920846-A1 BIOLOGICALLY MODIFIED VASCULAR GRAFTS FOR IMPROVED BYPASS SURGERY OUTCOMES The Board and Trustees of the Leland Stanford Junior University (US) 2021-12-15 EP claimed
WO-2020163654-A1 BIOLOGICALLY MODIFIED VASCULAR GRAFTS FOR IMPROVED BYPASS SURGERY OUTCOMES MCGRANE PAUL LEO (US) 2020-08-13 WO claimed
US-20200246127-A1 BIOLOGICALLY MODIFIED VASCULAR GRAFTS FOR IMPROVED BYPASS SURGERY OUTCOMES THE BOARD AND TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2020-08-06 US claimed
US-9603354-B2 Protective solutions for organs DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2017-03-28 US claimed
US-7977383-B2 Containing alkali ions, electrolytes, a buffer, polyol, saccharide and hydroxamic acid derivatives DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2011-07-12 US claimed
EP-1362511-B1 Protective solution for preventing ischaemia KOEHLER CHEMIE DR FRANZ (DE) 2011-03-30 EP claimed
CN-100448440-C Protective solution for preventing local ischemic damage FRANTZ KOLER DR CHEMICAL GMBH (DE) 2009-01-07 CN claimed
CN-1480132-A Protective solution for preventing local ischemic damage �����ġ����ղ�ʿ��ѧ���޹�˾ 2004-03-10 CN claimed
US-20030215781-A1 Protective solutions for organs DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2003-11-20 US claimed
EP-1362511-A1 Protective solution for preventing ischaemia Dr. Franz Köhler Chemie GmbH (DE) 2003-11-19 EP claimed
EP-4248959-A1 PREPARATION FOR REDUCTION OF PATHOLOGICAL IRON OVERLOAD Dr. Franz Köhler Chemie GmbH (DE) 2023-09-27 EP disclosed
US-20230181306-A1 BIOLOGICALLY MODIFIED VASCULAR GRAFTS FOR IMPROVED BYPASS SURGERY OUTCOMES THE BOARD AND TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2023-06-15 US disclosed
EP-3920846-A1 BIOLOGICALLY MODIFIED VASCULAR GRAFTS FOR IMPROVED BYPASS SURGERY OUTCOMES The Board and Trustees of the Leland Stanford Junior University (US) 2021-12-15 EP disclosed
WO-2020163654-A1 BIOLOGICALLY MODIFIED VASCULAR GRAFTS FOR IMPROVED BYPASS SURGERY OUTCOMES MCGRANE PAUL LEO (US) 2020-08-13 WO disclosed
CN-100448440-C Protective solution for preventing local ischemic damage FRANTZ KOLER DR CHEMICAL GMBH (DE) 2009-01-07 CN disclosed
EP-1859679-A1 Protective solution for preventing ischaemia damage Dr. Franz Köhler Chemie GmbH (DE) 2007-11-28 EP disclosed
CN-1480132-A Protective solution for preventing local ischemic damage �����ġ����ղ�ʿ��ѧ���޹�˾ 2004-03-10 CN disclosed
US-20030215781-A1 Protective solutions for organs DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2003-11-20 US disclosed
EP-1362511-A1 Protective solution for preventing ischaemia Dr. Franz Köhler Chemie GmbH (DE) 2003-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030215781-A1 Protective solutions for organs GLS, CA1, SI TSHR 3653/4885CYP2C9 4484/4885CYP2C19 4695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.